Phase 1 Study of How Three Forms of PF-08049820 Are Absorbed and Eliminated in Healthy Adults Including Effects of Food and Rabeprazole

What this Trial Is About

Researchers are evaluating how different forms of the study medicine PF-08049820 are absorbed and eliminated in healthy adults. The study aims to understand if taking the medicine with or without food affects absorption, and how absorption changes when taken with rabeprazole, a medicine that reduces stomach acid. This Phase 1 trial is focused on basic science to support future research. The study has two parts. In Part A, participants take three forms of PF-08049820 one at a time, each with or without food, for a total of five doses separated by several days. Participants stay in the clinic for about two weeks and receive a follow-up call about one month after the last dose. Part B may be conducted depending on Part A results, where participants take the three forms with or without food and with or without rabeprazole, totaling six doses. This phase lasts about three weeks followed by a follow-up phone call approximately one month later. During the study, participants will have regular assessments including blood sampling to measure drug concentration levels over time. Researchers will monitor safety through tracking adverse events, lab tests, vital signs, and ECGs. The main outcomes include measuring how much and how quickly PF-08049820 appears in the blood. Total participation time ranges from about two to three weeks in the clinic plus follow-up calls after dosing ends.

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults